0
Bio-Path Holdings, Inc. Banner Image

Bio-Path Holdings, Inc. has reached its limit for free report views

Work for Bio-Path Holdings, Inc.? Upgrade Your Profile and unlock all your annual reports.

Bio-Path Holdings, Inc.

  • Ticker BPTH
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Bio-Path Holdings, Inc. Logo Image
  • 1-10 Employees
  • Based in Bellaire, Texas
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and is under consideration by the FDA to commence Phase 1 studiesMore in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies
Bio-Path Holdings, Inc.

Most Recent Annual Report

Bio-Path Holdings, Inc. MOST RECENT 2020 Form 10K

Report Locked. Bio-Path Holdings, Inc. has reached its limit for free report views.